US FDA/NORD Partnership Will Further Increase Patient Involvement In Drug Development
Executive Summary
Agency's agreement with rare disease advocacy group will facilitate patient meetings with review divisions, as well as enhance communication of safety information.
You may also be interested in...
Generic Labeling Problems Targeted In US FDA Budget Request
Agency seeks legislative authority to update outdated generic drug labels when the reference product has been withdrawn.
US FDA Expands Patient Input To New Area: Orphan Grant Applications
Patient experience will be incorporated into agency orphan grant reviews, and outside rare disease experts will help make decisions.
US FDA Sets 'Low Bar' For Meetings With Patients
New request system is intended to boost FDA transparency, allow patients to more easily gain access to agency staff.